

2-1-2020

## Acoustic Parameters for Optimal Ultrasound-Triggered Release from Novel Spinal Hardware Devices.

Lauren J. Delaney  
*Thomas Jefferson University*

Cemile Basgul  
*Drexel University*

Daniel W MacDonald  
*Drexel University*

Keith Fitzgerald  
*Thomas Jefferson University*

Noreen J. Hickok  
*Thomas Jefferson University*

Follow this and additional works at: <https://jdc.jefferson.edu/radiologyfp>

 Part of the [For additional authors](#)

[Let us know how access to this document benefits you](#)

---

### Recommended Citation

Delaney, Lauren J.; Basgul, Cemile; MacDonald, Daniel W; Fitzgerald, Keith; Hickok, Noreen J.; Kurtz, Steven M; and Forsberg, Flemming, "Acoustic Parameters for Optimal Ultrasound-Triggered Release from Novel Spinal Hardware Devices." (2020). *Department of Radiology Faculty Papers*. Paper 129. <https://jdc.jefferson.edu/radiologyfp/129>

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Radiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: [JeffersonDigitalCommons@jefferson.edu](mailto:JeffersonDigitalCommons@jefferson.edu).

---

**Authors**

Lauren J. Delaney, Cemile Basgul, Daniel W MacDonald, Keith Fitzgerald, Noreen J. Hickok, Steven M Kurtz, and Flemming Forsberg

Acoustic Parameters for Optimal Ultrasound-Triggered Release from Novel Spinal Hardware  
Devices

Lauren J. Delaney <sup>a</sup>, Cemile Basgul <sup>b</sup>, Daniel W. MacDonald <sup>b</sup>, Keith Fitzgerald <sup>c</sup>, Noreen J.  
Hickok <sup>c</sup>, Steven M. Kurtz <sup>b,d</sup>, Flemming Forsberg <sup>a</sup>

<sup>a</sup> Department of Radiology, Thomas Jefferson University, 132 S. 10<sup>th</sup> Street, Philadelphia, PA  
19107, USA

<sup>b</sup> School of Biomedical Engineering, Science and Health Systems, Drexel University, 3141  
Chestnut Street, Philadelphia, PA 19104, USA

<sup>c</sup> Department of Orthopaedic Surgery, Thomas Jefferson University, 1015 Walnut Street,  
Philadelphia, PA 19107, USA

<sup>d</sup> Exponent, Inc., 3440 Market Street Suite 600, Philadelphia, PA 19104, USA

For correspondence/communicating author:

Flemming Forsberg, PhD

Department of Radiology

Thomas Jefferson University

132 S. 10<sup>th</sup> Street, Main 763

Philadelphia, PA 19107

1 (215) 955-4870

Flemming.fosberg@jefferson.edu

1    **Abstract**

2            Post-operative infection is a catastrophic complication of spinal fusion surgery, with up to  
3    10% occurrence, and existing preventative measures (i.e., peri-operative antibiotics) are only  
4    partially successful. To combat this clinical problem, we have designed a drug delivery system  
5    around polyetheretherketone (PEEK) clips to be used for prophylactic post-surgical release of  
6    antibiotics upon application of ultrasound. The overall hypothesis is that antimicrobial release from  
7    this system will aggressively combat post-surgical bacterial survival. This study investigated a set  
8    of acoustic parameters optimized for *in vitro* ultrasound-triggered coating rupture and subsequent  
9    release of encapsulated prophylactic antibiotics. We determined that a transducer frequency of 1.7  
10   MHz produced the most consistent burst release, and that at this frequency a pulse repetition  
11   frequency of 6.4 kHz and acoustic output power of 100% (3.41 MPa) produced the greatest release,  
12   representing an important proof of principle and the basis for continued development of this novel  
13   drug delivery system.

14

15   **Key words:** ultrasound-triggered release, polyetheretherketone PEEK, infection

16

17

18

## 1 **Introduction**

2           Bacterial infection following spinal fusion surgery is a major clinical concern, with up to  
3 10% of patients developing post-operative infection despite aggressive peri-operative antibiotic  
4 treatments (Dastgheyb, et al. 2015, Emohare, et al. 2014, Kurtz, et al. 2012, Molinari, et al. 2012).  
5 The current standard of care for preventing post-operative infection in spinal surgery is inclusion  
6 of 1-2 g of powdered vancomycin (VAN) into the surgical site during wound closure with the  
7 intention of achieving post-surgical sterilization (O'Neill, et al. 2011). However, the outcomes of  
8 this prophylactic procedure are mixed, due to the presence of wound drains that deplete the VAN  
9 at the surgical site within the first 48 hours. Additionally, VAN is active against Gram-positive  
10 bacteria (i.e., *Staphylococci*), but Gram-negative bacteria may be present in the wound and develop  
11 into an infection. [Left untreated, these remaining microbes can aggregate and form a biofilm on](#)  
12 [the implant surface, significantly complicating recovery \(Hall-Stoodley, et al. 2004, LuTheryn, et](#)  
13 [al. 2019\). In fact, biofilm formation is associated with up to 90% of chronic wound infections](#)  
14 [\(Bjarnsholt 2013, LuTheryn, et al. 2019\), and can lead to antibiotic resistance and recalcitrant](#)  
15 [infection \(LuTheryn, et al. 2019, Wolcott, et al. 2008, Delaney, et al. 2019\). Once this type of](#)  
16 infection develops, treatment often requires reopening the surgical site, and in extreme cases  
17 removal of the [bacterial-biofilm coated](#) spinal fusion hardware followed by additional revision  
18 surgeries (Collins, et al. 2008, Mok, et al. 2009). With only partially effective peri-operative  
19 antibiotic treatments in spinal fusion surgery, the cost and disability due to post-operative infection  
20 will continue to rise (Collins, et al. 2008, Emohare, et al. 2014, Kurtz, et al. 2012, Mok, et al.  
21 2009). Therefore, we aim to develop a more effective means to prevent infection to help address  
22 this clinical problem.

1           We hypothesize that supplementing the original supra-therapeutic concentrations of  
2 prophylactic antibiotics at the spinal fusion hardware site at a time when antibiotic concentrations  
3 are waning will lower the post-operative infection rates. In order to effectively combat post-  
4 operative infection, and at a molecular level, the formation of biofilms (Costerton, et al. 1999,  
5 Crosby, et al. 2016, Dastgheyb, et al. 2014, Rochford, et al. 2014), these new prophylactic  
6 treatment modalities should eradicate pathogens prior to adherence to the spinal hardware.  
7 Multiple studies have shown that bacteria adherence and subsequent biofilm formation, which is  
8 facilitated on the hardware surface, causes marked changes in bacterial antibiotic sensitivity due,  
9 at least in part, to alterations in gene expression as well as decreased metabolism (Costerton, et al.  
10 1999, Crosby, et al. 2016, Dastgheyb, et al. 2014, Dastgheyb, et al. 2015, [LuTheryn, et al. 2019](#)).  
11 Therefore, we aim to target any pathogens remaining in the wound site in the post-operative period  
12 with our ultrasound-triggered prophylactic delivery device.

13           To evaluate our hypothesis, we have developed a customized polyetheretherketone (PEEK)  
14 clip that is incorporated into existing spinal fusion hardware by clipping onto the spinal fusion rod  
15 (Delaney, et al. 2019). This clip is designed to contain a reservoir for drug-loading, which is then  
16 sealed with polylactic acid (PLA) to serve as a non-eluting vehicle. Application of ultrasound (US)  
17 to the thin PLA membrane that seals the drug-loaded reservoir in the clip will cause this thin  
18 membrane to rupture, thus triggering a local, bolus release of supra-therapeutic levels of  
19 combinations of prophylactic antibiotics to the surgical site. A representative diagram of this  
20 delivery system is shown in Figure 1.

21           Targeted US application can cause mechanical disruption of drug-containing micelles and  
22 micro- or nano-particles for drug delivery applications (Postema, et al. 2004, Prentice, et al. 2005,  
23 Sirsi and Borden 2014, Tanbour, et al. 2016, Zhang, et al. 2016), including those with polymeric

1 shells (Bevan, et al. 2007, Eisenbrey, et al. 2010, Jablonowski, et al. 2018, Jablonowski, et al.  
2 2017), and we intend to harness this technique for US-triggered drug delivery from our drug  
3 delivery system. One of the major advantages provided by this drug delivery system is that the  
4 release of antibiotics can be triggered and achieved at the discretion of the surgeon, without  
5 requiring additional surgery or invasive intervention. Additionally, application of US has been  
6 demonstrated to permeabilize biofilms that have formed on implant surfaces (Dong, et al. 2018,  
7 Harpaz 2000, Hu, et al. 2018), which is an added benefit of our delivery mechanism.

8         The purpose of this study was to determine the optimal acoustic parameters (transducer  
9 frequency, pulse repetition frequency (PRF), and acoustic output (AO) power) necessary for the  
10 *in vitro* destruction of a polymeric membrane surrounding a novel, prophylactic-containing, spinal  
11 PEEK-based clip to achieve complete release from within the device. The long-term goal is to  
12 achieve US-triggered release of antibiotics from within this spinal hardware to prevent post-  
13 surgical infection.

14

## 15 **Materials and Methods**

### 16 *Device Design*

17         C-shaped PEEK clips (1 cm diameter x 1 cm depth x 1 cm height) capable of clipping onto  
18 standard spinal fusion hardware, specifically the titanium rods used to stabilize the vertebrae, were  
19 designed with an internal drug reservoir (0.785 cm<sup>3</sup>) to house clinically-relevant amounts of  
20 deliverable bioactive materials for triggered release, as described previously (Basgul, et al. 2018,  
21 Delaney, et al. 2019). Briefly, spacer designs were drafted using Solidworks 2016 software  
22 (Dassault Systemes, Vélizy-Villacoublay, France) and the Simplify3D slicing program  
23 (Simplify3D, Cincinnati, OH), then the PEEK clips were 3D printed by our collaborators at Drexel

1 University using a PEEKMed filament on an Indmatec HPP 155/Gen 2 3D printer (Apium  
2 Additive Technologies, Karlsruhe, Germany). The outer-facing surface of the clip was printed with  
3 a circular opening 4 mm in diameter (cf., Fig. 1A) for loading the bioactive material into the  
4 reservoir. The internal reservoir volume was measured with microCT imaging (Scanco  $\mu$ CT 80,  
5 Scanco Medical, Brüttisellen, Switzerland).

6

### 7 *Device Loading and Preparation*

8 Methylene blue (MeB; Sigma Aldrich, St. Louis, MO), an intense dye that is widely used  
9 to visualize drug release (Bikram, et al. 2007, Satarkar and Hilt 2008, Sutani, et al. 2002, Wu, et  
10 al. 1996), was used to visualize structural integrity of the membrane before and after insonation,  
11 as well as to clearly assess the degree of US-triggered release. PEEK clips were loaded until filled  
12 (approximately 200  $\mu$ L) with a slurry of MeB, and then frozen at  $-20^{\circ}$  C overnight to solidify the  
13 contents for coating with the thin PLA membrane. Loaded clips were coated by submersion and  
14 withdrawal in a solution of 1.5 g Resomer Select 100 DL 7E PLA (Evonik Biomaterials, Essen,  
15 Germany) in 30 mL chloroform (Fisher Scientific, Hampton, NH) and dried to create a thin coating  
16 on the spacer surface, encapsulating the MeB within the clip reservoir. All clips were dried under  
17 continuous air-flow at room temperature for 24 hours. This coating process was repeated four  
18 times to create a stable coating across the reservoir. Coated, loaded clips were kept at  $-20^{\circ}$  C until  
19 used for testing.

20

### 21 *Determination of US Parameters for Triggered Release*

22 Transducer frequency, pulse repetition frequency (PRF), and acoustic output (AO) power  
23 were the three parameters sequentially evaluated in this study. Coated clips were submerged in



1 water to mimic the biological environment, and allowed to rest for 5 minutes to ensure no leaks  
2 from the PLA coating. Submerged clips were then insonated for 10 minutes using a Logiq E9  
3 clinical US scanner (GE Healthcare, Waukesha, WI) equipped with a C1-6 curvilinear probe, using  
4 grayscale imaging (4.0 MHz) to establish the position of the spacer, and then power Doppler  
5 imaging (MI 1.2) to induce cavitation and rupture of the PLA coating for MeB release. The probe  
6 was positioned directly over the spacer, and held there with a clamp for the duration of the  
7 scanning, with a layer of gel between the transducer and water bag to best approximate clinical  
8 conditions.

9 We hypothesized that selecting a value at the lower end, middle, and higher end of the  
10 range for each of the acoustic parameters evaluated in this study would provide a comprehensive  
11 evaluation of this parameter space (Shi, et al. 2006). To evaluate this hypothesis, we followed a  
12 step-wise procedure to determine the optimal parameter value to induce membrane rupture and  
13 subsequent dye release starting with evaluation of transducer frequency, then holding the  
14 determined optimal frequency while evaluating PRF, and finally holding both optimal frequency  
15 and PRF while evaluating AO power. Initially, transducer frequency was varied, while holding the  
16 preset PRF of 1.1 kHz and 100% AO power.

17 Transducer frequencies evaluated were 1.7, 2.5, and 3.6 MHz, while AO energy was held  
18 at 100%. The frequency that resulted in the most consistent membrane rupture and subsequent  
19 MeB release was chosen as optimal. Once the optimal transducer frequency was chosen, PRF was  
20 evaluated at 0.1, 3.5, and 6.4 kHz at 100% AO power. Finally, the optimal transducer frequency  
21 and PRF were held while AO power was varied (30, 60, and 100%). Peak-to-peak pressures of  
22 these three AO power settings were measured with a 0.5 mm needle hydrophone (Precision  
23 Acoustics, Dorchester, UK). Briefly, the hydrophone was calibrated and placed into the US beam

1 at each of the study settings, and pressure measurements were taken in triplicate. Additionally,  
2 uninsonated negative controls (designated 0% AO power) were evaluated for any passive leakage  
3 during the duration of testing. Resulting MeB release was evaluated qualitatively against known  
4 MeB concentration standards immediately following insonation and again 24 hours after  
5 insonation, as appropriate to this specific study. Briefly, the degree of blue dye within the water  
6 bath at each timepoint was compared against solutions with known MeB concentrations relevant  
7 to the loading conditions in this study. The overall amount of MeB released was then calculated  
8 from the volume of the water bath and the matching MeB concentration. Clips were also visually  
9 inspected for PLA membrane rupture 24 hours after insonation.

10

#### 11 *Statistical Analysis*

12 Results were collected in triplicate (n = 3 for each evaluated US parameter plus negative  
13 control; n = 21 total). Error represents standard error about the mean (SEAM). Statistical analysis  
14 was performed with GraphPad Prism 7 (GraphPad, La Jolla, CA) using a one-way ANOVA  
15 analysis to determine significance between groups (for  $\alpha < 0.05$ ), with Bonferroni correction for  
16 multiple comparisons and Tukey's multiple comparison post-test when appropriate.

17

#### 18 **Results and Discussion**

19 For the purposes of this experiment, a successful device would retain the encapsulated  
20 material until insonated, upon which the encapsulating membrane would rupture causing a burst  
21 release of the encapsulated material. Therefore, we are evaluating the acoustic parameters  
22 described in this study to determine the settings that most consistently meet these criteria for a  
23 successful targeted release. In all cases, the PLA membrane was successfully ruptured by

1 application of US. A representative collage of the scanning setup and resulting MeB release is  
2 shown in Figure 2. Panel A shows the overall setup before the transducer is activated, while Panels  
3 B and C show the MeB release as a result of US-triggered rupture of the PLA membrane, **visualized**  
4 **as a blue stream emerging from the reservoir opening**. Panel D shows the complete emptying of  
5 the encapsulated MeB from within the clip several hours after insonation. Additionally,  
6 representative images of the US scanning parameters are shown in Figure 3, where the standard  
7 B-mode image (Figure 3A) is used for positioning the transducer, and then power Doppler (Figure  
8 3B) is activated to induce PLA membrane rupture. **The orange areas within the power Doppler box**  
9 **correspond to imaging artifact, as there is no blood flow occurring within the sample**. The power  
10 Doppler scanning parameters were modified as described previously to determine the optimal  
11 parameters for membrane rupture and MeB release. Finally, before and after photos of a MeB-  
12 loaded, PLA-coated device are shown in Figure 4, demonstrating the successful rupture of the PLA  
13 membrane to allow for release of the encapsulated MeB from within the clip.

14

#### 15 *Determination of Optimal Transducer Frequency*

16 All three frequencies evaluated resulted in PLA membrane rupture and subsequent MeB  
17 release. Results of US-triggered release based on transducer frequency are summarized in Figure  
18 5. There was no significant difference in the immediate burst release from the PEEK clips at the  
19 three transducer frequencies evaluated ( $p = 0.48$ ), with 1.7 MHz producing  $33.8 \pm 7.8\%$  release  
20 ( $0.23 \pm 0.05$  mg/mL), 2.5 MHz producing  $31.3 \pm 6.3\%$  ( $0.21 \pm 0.04$  mg/mL), and 3.6 MHz  
21 producing  $42.5 \pm 5.0\%$  ( $0.28 \pm 0.03$  mg/mL). After 24 hours, there was still no significant  
22 difference in MeB release between the transducer frequencies evaluated in this study ( $p = 0.27$ ).  
23 The 1.7 MHz setting resulted in a cumulative release of  $72.5 \pm 17.5\%$  ( $0.48 \pm 0.12$  mg/mL), while

1 2.5 MHz yielded  $92.5 \pm 10.9\%$  cumulative release ( $0.62 \pm 0.07$  mg/mL) and 3.6 MHz produced  
2  $102.5 \pm 2.5\%$  cumulative MeB release ( $0.68 \pm 0.02$  mg/mL). Due to the nature of the qualitative  
3 MeB release measurements and the intensity of the MeB stain, it is not unexpected to observe a  
4 cumulative MeB release greater than 100%, and we believe that our observed results are within  
5 reason given the standard deviation of the reported average.

6        Ultrasound intensity lost to attenuation in tissues increase as the frequency of the  
7 ultrasound beam increases. Generally, the attenuation coefficient is 0.5 to 1 dB/cm traveled in the  
8 medium per MHz of transmit frequency (Bushberg, et al. 1994). Therefore, by selecting the lowest  
9 transmit frequency that allows for membrane rupture, we can effectively reduce the amount of  
10 signal attenuation in the surrounding tissues. Additionally, studies have shown that rupture of  
11 membranes is improved at lower US frequencies (Cohen-Levi, et al. 2000, Schroeder, et al. 2007).  
12 Considering these physical phenomena, coupled with the finding that there were no significant  
13 differences in immediate burst release between the three evaluated transducer frequencies ( $p >$   
14  $0.99$ ), we selected 1.7 MHz as the optimal frequency for burst release from these PLA-coated  
15 PEEK clips to account for signal attenuation in future *in vivo* applications.

16

### 17 *Determination of Optimal PRF*

18        The frequency of 1.7 MHz was maintained, while the PRF was varied to further optimize  
19 US parameters. Similar to the frequency experiments, all three PRFs evaluated resulted in  
20 membrane rupture and MeB release. Results of US-triggered release based on pulse repetition  
21 frequency are shown in Figure 6. However, unlike the transducer frequencies, there was a  
22 significant difference in resulting immediate burst release of MeB as a result of varying the PRF  
23 ( $p = 0.021$ ). A PRF of 0.1 kHz resulted in significantly less immediate burst release of MeB (17.5

1  $\pm 1.3\%$  corresponding to  $0.12 \pm 0.01$  mg/mL) than 6.4 kHz ( $36.3 \pm 5.4\%$  corresponding to  $0.24 \pm$   
2  $0.04$  mg/mL,  $p = 0.029$ ). There was no significant difference in immediate burst release between  
3 6.4 kHz and 3.5 kHz ( $32.5 \pm 2.5\%$  corresponding to  $0.22 \pm 0.02$  mg/mL,  $p > 0.99$ ), and the  
4 difference between 0.1 kHz and 3.5 kHz was trending toward significance ( $p = 0.07$ ).

5         After 24 hours, however, no significant differences in cumulative MeB release remained  
6 between the three PRFs evaluated in this study ( $p = 0.06$ ). The 0.1 kHz setting resulted in a  
7 cumulative release of  $66.0 \pm 10.0\%$  ( $0.43 \pm 0.06$  mg/mL), while 3.5 kHz yielded  $75.0 \pm 8.7\%$   
8 cumulative release ( $0.50 \pm 0.06$  mg/mL) and 6.4 kHz produced  $112.0 \pm 19.1\%$  cumulative MeB  
9 release ( $0.66 \pm 0.04$  mg/mL). [Again, given the standard deviation and the nature of these](#)  
10 [experiments, an average cumulative release over 100% is not unexpected.](#) One limitation to this  
11 study is the intensity of MeB at increased concentrations, as we found that this potent dye resulted  
12 in solution saturation at the 24 hour observation point. This may have clouded the results at this  
13 second time point, hiding any potential significant differences in cumulative release from within  
14 the clips. Therefore, we place greater influence on the immediate burst release results in  
15 determining the optimal acoustic parameters, as the differences in MeB concentration are more  
16 distinguishable at this time point. As such, we were able to rule out the PRF setting of 0.1 kHz as  
17 ineffective for membrane rupture.

18         We did not observe any significant difference in immediate burst release between 3.5 and  
19 6.4 kHz, suggesting that, over a certain threshold, the frequency of pulses does not have a  
20 significant impact on membrane rupture. Similarly, others have found that drug release profiles  
21 from liposomes were similar for continuous and pulsed low frequency US, and that exposure time  
22 is a more critical factor (Schroeder, et al. 2007). While there were no significant differences in  
23 burst or cumulative release between the PRF settings of 3.5 and 6.4 kHz, there was greater overall

1 MeB release from the clips insonated with a PRF of 6.4 kHz. Additionally, since insonation of the  
2 spinal fusion clip does not require the US wave to penetrate deep into tissue, *but only through thin*  
3 *skeletal muscle tissues of the back*, the PRF in our system is not *significantly* limited by ambiguity  
4 of echoed signals (Bushberg, et al. 1994). Therefore, we selected 6.4 kHz as the optimal PRF for  
5 membrane rupture for the parameter space considered in this study.

6

### 7 *Determination of Optimal Acoustic Output Power*

8 Finally, AO power was evaluated, while transducer frequency (1.7 MHz) and PRF (6.4  
9 kHz) were maintained. AO powers tested were 30, 60, and 100%, which corresponded to peak-to-  
10 peak pressures of  $2.33 \pm 0.03$ ,  $2.72 \pm 0.04$ , and  $3.41 \pm 0.01$  MPa, respectively. Additionally,  
11 uninsonated controls (0% AO power, 0.00 MPa peak-to-peak pressure) were evaluated to  
12 determine any passive leakage from the membrane over the 24 hour incubation period. The results  
13 of these experiments are presented in Figure 7. Uninsonated controls exhibited only  $1.3 \pm 1.2\%$   
14  $(0.01 \pm 0.01 \text{ mg/mL})$  immediate release ( $p = 0.031$  compared to 60% AO power and  $p = 0.007$   
15 compared to 100% AO power), and  $6.8 \pm 2.8\%$   $(0.05 \pm 0.02 \text{ mg/mL})$  cumulative release ( $p =$   
16  $0.021$  compared to 30% AO power,  $p = 0.006$  compared to 60% AO power, and  $p = 0.002$   
17 compared to 100% AO power) confirming US-triggered release in the insonated samples as  
18 opposed to just passive leakage. Some minor background release was observed upon submersion  
19 of some the clips in water, suggesting that the PLA membrane is not consistently stable under  
20 simulated biological conditions. Currently, we are investigating methods to improve the stability  
21 of the PLA coating membrane, including 3D-printed PLA sheets and spray application.

22 There was no significant difference in immediate burst release of MeB between the three  
23 AO powers evaluated, but the results were trending toward significance ( $p = 0.07$ ). Specifically,

1 30% AO resulted in  $12.5 \pm 6.6\%$  ( $0.08 \pm 0.04$  mg/mL) release, 60% AO produced  $27.5 \pm 6.6\%$   
2 ( $0.18 \pm 0.04$  mg/mL), and 100% AO yielded  $35.0 \pm 2.5\%$  ( $0.23 \pm 0.02$  mg/mL) immediate burst  
3 release of MeB in response to insonation. While 30% AO power appears to have produced much  
4 less immediate MeB release than 100% AO power, these results were only trending toward  
5 significance ( $p = 0.08$ ). After 24 hours, there remained no significant difference in cumulative  
6 MeB release from the insonated clips ( $p = 0.39$ ), again likely due to the intensity and solution  
7 saturation of MeB at higher concentrations. Cumulative MeB release at 30% AO power was  $75.0$   
8  $\pm 21.7\%$  ( $0.50 \pm 0.14$  mg/mL), while 60% AO power resulted in  $90.0 \pm 8.7\%$  ( $0.60 \pm 0.06$  mg/mL)  
9 and 100% AO power yielded  $103.5 \pm 0.9\%$  ( $0.69 \pm 0.01$  mg/mL) cumulative release.

10         Interestingly, there was no significant difference in immediate burst release between 0%  
11 AO power and 30% AO power ( $p = 0.85$ ), suggesting that 30% was not strong enough to  
12 completely rupture the PLA membrane for effective immediate burst release. However, after 24  
13 hours, there was significantly greater cumulative MeB release from the sample insonated at 30%  
14 AO power compared to the 0% control ( $p = 0.021$ ), suggesting that this low power insonation  
15 induced some damage to the PLA membrane that allowed for long-term slow release of the  
16 encapsulated MeB, just not enough to cause catastrophic membrane rupture and significant burst  
17 release immediately upon insonation. While slow elution is often used to treat  
18 establishing/established infection, the burst release is more desirable as it will sterilize the area  
19 around the implant and, due to its supra-therapeutic levels, not foster the possibility of acquisition  
20 of resistance (Dastgheyb, et al. 2015, Delaney, et al. 2019, Lewis 2008). Additionally, the  
21 temporary absence of antibiotic pressure followed by a secondary supra-therapeutic dose may help  
22 eradicate any organisms that were less susceptible to the primary treatment due to a persister  
23 phenotype (Costerton, et al. 1999, Dastgheyb, et al. 2015, Delaney, et al. 2019, Lewis 2008).

1           While there were no significant differences in MeB release between 60% and 100% AO  
2 power, we observed more consistent membrane rupture and greater overall MeB release from the  
3 samples insonated with 100% AO power. Moreover, the use of 100% will better counteract  
4 attenuation of the US beam in human tissue, providing a signal that is still strong enough to induce  
5 membrane rupture upon reaching the clip in its anatomical position. Hence, 100% AO power was  
6 chosen as the optimal output power within this parameter space.

7           Although the study findings are encouraging, several limitations must be discussed. An  
8 important limitation to this study was the small sample size. We made approximately 6 loaded,  
9 and hand-coated clips for each testing parameter, but some of these leaked prematurely or had  
10 other fabrication defects. As a result, we were able to get consistent behavior from only 3 clips per  
11 group. However, this still represents a large enough sample size for statistical comparisons, as we  
12 consider it appropriate for this proof of concept study. As previously mentioned, we found that the  
13 handcrafted PLA coating efficiency was inconsistent across PEEK clip samples, with some leaking  
14 immediately upon introduction to water and some not rupturing at all in response to insonation.  
15 As such, future work will include developing methods to standardize the PLA coating for more  
16 consistent sealing of the reservoir, [including investigation of 3D printed capping lids for the](#)  
17 [reservoir and spray coating of the PLA layer.](#) However, we have previously demonstrated the long-  
18 [term \(7 day\) stability of the PLA layer \(Delaney, et al. 2019\), and are confident that the bulk of](#)  
19 [the encapsulated material would remain contained within the device until insonation. Remaining](#)  
20 [PLA material will be hydrolyzed into lactic acid over time and naturally secreted.](#) Overall, there  
21 was no significant difference in cumulative release after 24 hours for any of the evaluated acoustic  
22 parameters ( $p > 0.50$ ), likely due to the saturation effects of MeB dye in solution as discussed  
23 previously. Ongoing work includes the use of antibiotics or other bioactive compounds that are



1 more readily quantified by more precise means and are not subject to visual saturation.  
2 Nonetheless, the MeB allowed for clear visual confirmation of membrane rupture and provided  
3 important information about the PLA membrane stability, serving as an appropriate model in these  
4 proof of concept experiments. Finally, we recognize that the acoustic parameters evaluated in this  
5 study represent only a subset of the totality for frequency, PRF, and AO power. The test values  
6 chosen for each parameter were based on the settings available on the Logiq E9, and represent the  
7 lowest, highest, and middle points on the ranges of available settings. Additional studies are needed  
8 to more completely optimize the acoustic parameters for PLA coating rupture and subsequent  
9 release, including manipulation of duty cycle, pulse shape, insonation time, and therapy times.  
10 Nonetheless, these results represent a proof of principle and basis for these continued studies,  
11 especially as we prepare to move into an *in vivo* model. In summary, a transducer frequency of 1.7  
12 MHz, a PRF of 6.4 kHz, and 100% AO power was determined to be optimal for US-triggered  
13 release for the parameter space studied here. These settings ultimately resulted in a total peak-to-  
14 peak pressure of  $3.41 \pm 0.01$  MPa, which is well within the acceptable limits for clinical US  
15 scanners (Barnett, et al. 2000, Duck and Henderson 1998).

16

## 17 **Conclusions**

18 Post-operative infection is a catastrophic and far too frequent complication of spinal fusion  
19 surgery (occurrence rate of up to 10%), with existing preventative measures being only partially  
20 successful. To combat this clinical problem, we have designed a drug release system to be used in  
21 spinal surgeries for prophylactic post-surgical release of combinations of antibiotics (i.e., both  
22 Gram-positive and Gram-negative targets) upon US application 5-7 days after surgery or at the  
23 surgeon's discretion. We believe that this system will aggressively combat the survival of bacteria

1 contaminating the surgical site, while also allowing versatility in loading capacity (i.e. combination  
2 of Gram-positive and Gram-negative antibiotics), providing a tailored solution to the clinical  
3 problem that we feel is superior to controlled, prolonged release systems. This study represents a  
4 proof of principle and basis for continued development of this US-triggered drug delivery system.  
5 We have successfully determined a set of primary US scanning parameters (1.7 MHz transmit  
6 frequency, 6.4 kHz PRF, and 100% AO power, corresponding to 3.41 MPa peak-to-peak pressure)  
7 that are appropriate for US-triggered rupture of the encapsulating PLA membrane and the  
8 subsequent release of encapsulated bioagents. While minimal background release was observed  
9 from some of the devices, overall we have demonstrated significant burst release of encapsulated  
10 materials upon insonation compared to uninsonated controls. These results serve as an important  
11 initial step towards deployment of this prophylactic device.

12

### 13 **Acknowledgements**

14 The authors wish to acknowledge Dr. Christopher Kepler from the Rothman Institute for his  
15 helpful discussions about clinical implications and Dr. Priscilla Machado from Thomas Jefferson  
16 University for her contribution to this project. Additionally, we thank GE Healthcare for equipment  
17 support. This project was funded by NIH grants R01 AR069119 and F32 AR072491.

18

19

1 **Figure Captions List**

2 *Figure 1: Representation of novel spinal hardware. A) Drawing of loaded, coated PEEK clip. B)*  
3 *US-triggered release from anatomical positioning on spinal fusion hardware.*

4

5 *Figure 2: Representative images of the ultrasound scanning setup for triggering membrane*  
6 *rupture and MeB release. A) Setup as a whole prior to insonation, showing the clip submerged in*  
7 *water and positioned under the transducer. B) Image of initial PLA membrane rupture and*  
8 *resulting MeB release. C) US-triggered MeB release from ruptured PLA membrane, with fluid*  
9 *streaming from within the clip. D) Resulting complete MeB release from within the clip following*  
10 *insonation.*

11

12 *Figure 3: Ultrasound imaging of MeB-loaded, PLA-coated PEEK coated. A) Grayscale image of*  
13 *spacer. B) Power Doppler scanning of spacer.*

14

15 *Figure 4: Representative images of MeB-loaded, PLA-coated PEEK spacer. A) Spacer prior to*  
16 *insonation with intact PLA coating. B) Spacer after insonation, with fully ruptured PLA coating.*

17

18 *Figure 5: Summarized results of US-triggered MeB release based on transducer frequency,  $n = 3$ ,*  
19 *error bars represent standard error about the mean.*

20

1 *Figure 6: Summarized results of US-triggered MeB release based on pulse repetition frequency,*  
2 *\*p = 0.029 between 0.1 kHz and 6.4 kHz immediate burst release, n = 3, error bars represent*  
3 *standard error about the mean.*

4  
5 *Figure 7: Summarized results of US-triggered MeB release based on acoustic output power, with*  
6 *0% AO power negative controls, top\*p < 0.02 for MeB cumulative release from 0% AO power*  
7 *being significantly less than the other 3 parameters, bottom\*p < 0.03 for immediate burst release*  
8 *of MeB from 0% AO power compared to 60% and 100% AO powers (0% vs. 30% not significant,*  
9 *p = 0.85), n = 3, error bars represent standard error about the mean.*

1 **References**

- 2 Barnett SB, Ter Haar GR, Ziskin MC, Rott H-D, Duck FA, Maeda K. International  
3 recommendations and guidelines for the safe use of diagnostic ultrasound in medicine.  
4 *Ultrasound Med Biol* 2000; 26:355-66.
- 5 Basgul C, Yu T, MacDonald DW, Siskey R, Marcolongo M, Kurtz SM. Structure–property  
6 relationships for 3D-printed PEEK intervertebral lumbar cages produced using fused  
7 filament fabrication. *J Mater Res* 2018:1-12.
- 8 Bevan PD, Karshafian R, Tickner EG, Burns PN. Quantitative measurement of ultrasound  
9 disruption of polymer-shelled microbubbles. *Ultrasound Med Biol* 2007; 33:1777-86.
- 10 Bikram M, Gobin AM, Whitmire RE, West JL. Temperature-sensitive hydrogels with SiO<sub>2</sub>–Au  
11 nanoshells for controlled drug delivery. *J Control Release* 2007; 123:219-27.
- 12 [Bjarnsholt T. The role of bacterial biofilms in chronic infections. \*APMIS\* 2013; 121:1-58.](#)
- 13 Bushberg JT, Seibert JA, Leidholdt Jr EM, Boone JM. The essential physics of medical imaging.  
14 Baltimore, Maryland: Williams & Wilkins, 1994.
- 15 Cohen-Levi D, Kost J, Barenholz Y. Ultrasound for targeted delivery of cytotoxic drugs from  
16 liposomes. Beer Sheva, Israel: Ben Gurion University 2000.
- 17 Collins I, Wilson-MacDonald J, Chami G, Burgoyne W, Vinayakam P, Berendt T, Fairbank J.  
18 The diagnosis and management of infection following instrumented spinal fusion. *Eur*  
19 *Spine J* 2008; 17:445-50.
- 20 Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent  
21 infections. *Science* 1999; 284:1318-22.

1 Crosby HA, Kwiecinski J, Horswill AR. Staphylococcus aureus Aggregation and Coagulation  
2 Mechanisms, and Their Function in Host-Pathogen Interactions. *Adv Appl Microbiol*  
3 2016; 96:1-41.

4 Dastgheyb S, Parvizi J, Shapiro IM, Hickok NJ, Otto M. Effect of biofilms on recalcitrance of  
5 staphylococcal joint infection to antibiotic treatment. *J Infect Dis* 2014; 211:641-50.

6 Dastgheyb SS, Hammoud S, Ketonis C, Liu AY, Fitzgerald K, Parvizi J, Purtill J, Ciccotti M,  
7 Shapiro IM, Otto M, Hickok NJ. Staphylococcal persistence due to biofilm formation in  
8 synovial fluid containing prophylactic cefazolin. *Antimicrob Agents Chemother* 2015;  
9 59:2122-28.

10 Delaney LJ, MacDonald D, Leung J, Fitzgerald K, Sevit AM, Eisenbrey JR, Patel N, Forsberg F,  
11 Kepler CK, Fang T, Kurtz SM, Hickok NJ. Ultrasound-triggered antibiotic release from  
12 PEEK clips to prevent spinal fusion infection: Initial evaluations. *Acta Biomater* 2019;  
13 93:12-24.

14 Dong Y, Li J, Li P, Yu J. Ultrasound microbubbles enhance the activity of vancomycin against  
15 Staphylococcus epidermidis biofilms in vivo. *J Ultrasound Med* 2018; 37:1379-87.

16 Duck F, Henderson J. Acoustic output of modern ultrasound equipment: is it increasing. *Safety*  
17 *of diagnostic ultrasound*. The Parthenon Publishing Group, New York London 1998:15-  
18 25.

19 Eisenbrey J, Burstein OM, Kambhampati R, Forsberg F, Liu J-B, Wheatley M. Development and  
20 optimization of a doxorubicin loaded poly (lactic acid) contrast agent for ultrasound  
21 directed drug delivery. *J Control Release* 2010; 143:38-44.

22 Emohare O, Ledonio CG, Hill BW, Davis RA, Polly Jr DW, Kang MM. Cost savings analysis of  
23 intrawound vancomycin powder in posterior spinal surgery. *Spine J* 2014; 14:2710-15.

1 Harpaz D. Ultrasound enhancement of thrombolytic therapy: observations and mechanisms. *Int J*  
2 *Cardiovasc Intervent* 2000; 3:81-89.

3 [Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to](#)  
4 [infectious diseases. \*Nat Rev Microbiol\* 2004; 2:95-108.](#)

5 Hu J, Zhang N, Li L, Ma Y, Zhao C, Wu Q, Li Y, He N, Wang X. The synergistic bactericidal  
6 effect of vancomycin on UTMD treated biofilm involves damage to bacterial cells and  
7 enhancement of metabolic activities. *Sci Rep* 2018; 8:192.

8 Jablonowski LJ, Conover D, Teraphongphom NT, Wheatley MA. Manipulating multifaceted  
9 microbubble shell composition to target both TRAIL-sensitive and resistant cells. *J*  
10 *Biomed Mater Res A* 2018; 106:1903-15.

11 Jablonowski LJ, Teraphongphom NT, Wheatley MA. Drug delivery from a multi-faceted  
12 ultrasound contrast agent: influence of shell composition. *Mol Pharm* 2017; 14:3448-56.

13 Kurtz SM, Lau E, Ong KL, Carreon L, Watson H, Albert T, Glassman S. Infection risk for  
14 primary and revision instrumented lumbar spine fusion in the Medicare population. *J*  
15 *Neurosurg Spine* 2012; 17:342-7.

16 Lewis K. Multidrug tolerance of biofilms and persister cells. *Bacterial Biofilms*: Springer, 2008.  
17 107-31.

18 [LuTheryn G, Glynn-Jones P, Webb JS, Carugo D. Ultrasound-mediated therapies for the](#)  
19 [treatment of biofilms in chronic wounds: a review of present knowledge. \*Microb\*](#)  
20 [Biotechnol](#) 2019; published online ahead of print [https://doi.org/10.1111/1751-](https://doi.org/10.1111/1751-7915.13471)  
21 [7915.13471](https://doi.org/10.1111/1751-7915.13471).

1 Mok JM, Guillaume TJ, Talu U, Berven SH, Deviren V, Kroeber M, Bradford DS, Hu SS.  
2 Clinical outcome of deep wound infection after instrumented posterior spinal fusion: a  
3 matched cohort analysis. *Spine* 2009; 34:578-83.

4 Molinari RW, Khera OA, Molinari III WJ. Prophylactic intraoperative powdered vancomycin  
5 and postoperative deep spinal wound infection: 1,512 consecutive surgical cases over a 6-  
6 year period. *Eur Spine J* 2012; 21:476-82.

7 O'Neill KR, Smith JG, Abtahi AM, Archer KR, Spengler DM, McGirt MJ, Devin CJ. Reduced  
8 surgical site infections in patients undergoing posterior spinal stabilization of traumatic  
9 injuries using vancomycin powder. *Spine J* 2011; 11:641-6.

10 Postema M, Van Wamel A, Lancée CT, De Jong N. Ultrasound-induced encapsulated  
11 microbubble phenomena. *Ultrasound Med Biol* 2004; 30:827-40.

12 Prentice P, Cuschieri A, Dholakia K, Prausnitz M, Campbell P. Membrane disruption by  
13 optically controlled microbubble cavitation. *Nat Phys* 2005; 1:107-10.

14 Rochford ET, Poulsson AH, Salavarieta Varela J, Lezuo P, Richards RG, Moriarty TF. Bacterial  
15 adhesion to orthopaedic implant materials and a novel oxygen plasma modified PEEK  
16 surface. *Colloids Surf B Biointerfaces* 2014; 113:213-22.

17 Satarkar NS, Hilt JZ. Magnetic hydrogel nanocomposites for remote controlled pulsatile drug  
18 release. *J Control Release* 2008; 130:246-51.

19 Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, Kost J, Barenholz Y.  
20 Controlling Liposomal Drug Release with Low Frequency Ultrasound: Mechanism and  
21 Feasibility. *Langmuir* 2007; 23:4019-25.



1 Shi WT, Forsberg F, Vaidyanathan P, Tornes A, Østensen J, Goldberg BB. The influence of  
2 acoustic transmit parameters on the destruction of contrast microbubbles in vitro. *Phys*  
3 *Med Biol* 2006; 51:4031.

4 Sirsi SR, Borden MA. State-of-the-art materials for ultrasound-triggered drug delivery. *Adv*  
5 *Drug Deliv Rev* 2014; 72:3-14.

6 Sutani K, Kaetsu I, Uchida K, Matsubara Y. Stimulus responsive drug release from polymer gel:  
7 Controlled release of ionic drug from polyampholyte gel. *Radiat Phys Chem* 2002;  
8 64:331-36.

9 Tanbour R, M Martins A, G Pitt W, A Hussein G. Drug delivery systems based on polymeric  
10 micelles and ultrasound: a review. *Curr Pharm Des* 2016; 22:2796-807.

11 [Wolcott RD, Rhoads DD, Dowd SE. Biofilms and chronic wound inflammation. \*J Wound Care\*](#)  
12 [2008, 17:333-341.](#)

13 Wu BM, Borland SW, Giordano RA, Cima LG, Sachs EM, Cima MJ. Solid free-form fabrication  
14 of drug delivery devices. *J Control Release* 1996; 40:77-87.

15 Zhang Y, Yu J, Bomba HN, Zhu Y, Gu Z. Mechanical force-triggered drug delivery. *Chem Rev*  
16 2016; 116:12536-63.